InnoCan Pharma Corporation

Consumer Defensive CA INNO

2.9CAD
-0.25(7.94%)

Last update at 2026-06-22T13:41:00Z

Day Range

2.902.90

LowHigh

52 Week Range

0.1521.00

LowHigh

Fundamentals

Previous Close 3.15
Market Cap28.43M
Volume0
P/E Ratio-
Dividend Yield-%
EBITDA-1.21300M
Revenue TTM26.61M
Revenue Per Share TTM5.94
Gross Profit TTM 23.93M
Diluted EPS TTM-0.34

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	0.09M	0.92M	-4.03400M	-3.88800M	-10.09100M
Minority interest	-0.78300M	-1.57200M	-0.45200M	0.12M	0.04M
Net income	-1.12400M	-1.83400M	-4.70000M	-3.76400M	-10.04700M
Selling general administrative	24.25M	25.89M	13.98M	6.85M	6.20M
Selling and marketing expenses	-	-	-	-	-
Gross profit	23.93M	26.19M	11.98M	2.11M	0.12M
Reconciled depreciation	0.04M	0.04M	0.03M	0.04M	0.04M
Ebit	-	-	-	-	-7.48000M
Ebitda	-	-	-	-3.85100M	-10.03500M
Depreciation and amortization	-	-	-	-	-
Non operating income net other	-	-	-	-	-
Operating income	-1.25500M	-1.24700M	-3.80300M	-6.26600M	-7.48000M
Other operating expenses	-	-	-	-	-
Interest expense	0.00300M	0.00700M	0.00000M	0.00200M	0.01M
Tax provision	0.43M	1.18M	0.21M	0.00100M	0.00000M
Interest income	-	0.00000M	0.02M	0.02M	-
Net interest income	-0.00300M	-0.00700M	0.02M	0.02M	-0.01300M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	-	-	-	-
Total revenue	26.61M	29.44M	13.66M	2.56M	0.20M
Total operating expenses	27.87M	30.68M	17.46M	8.82M	7.68M
Cost of revenue	2.68M	3.25M	1.68M	0.45M	0.07M
Total other income expense net	1.34M	2.17M	-0.25400M	2.36M	-2.59800M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-0.34100M	-0.26200M	-4.24800M	-3.88900M	-10.09100M
Net income applicable to common shares	-	-	-	-	-10.04700M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	10.52M	9.26M	6.94M	6.98M	12.57M
Intangible assets	-	-	-	-	-
Earning assets	-	-	-	-	-
Other current assets	-	0.15M	0.03M	-	0.08M
Total liab	2.29M	2.24M	2.55M	0.75M	3.56M
Total stockholder equity	5.60M	5.17M	4.10M	6.39M	9.05M
Deferred long term liab	-	-	-	-	-
Other current liab	0.39M	1.56M	1.95M	0.30M	3.08M
Common stock	-	-	-	-	-
Capital stock	0.00000M	0.00000M	0.00000M	0.00000M	0.00000M
Retained earnings	-36.03200M	-34.90800M	-33.07400M	-28.37400M	-24.61000M
Other liab	-	-	-	-	-
Good will	-	-	-	-	-
Other assets	-	-	-	-	-
Cash	6.69M	5.01M	3.88M	4.95M	11.05M
Cash and equivalents	-	-	-	-	-
Total current liabilities	1.35M	2.24M	2.54M	0.73M	3.56M
Current deferred revenue	-	-	-	-	-
Net debt	-	-	-	-	-
Short term debt	-	-	-	-	-
Short long term debt	-	-	-	-	-
Short long term debt total	-	-	-	-	-
Other stockholder equity	-	-	-	-	-
Property plant equipment	-	-	-	-	0.05M
Total current assets	10.44M	9.15M	6.80M	6.88M	12.52M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	-	9.05M
Short term investments	-	-	-	-	-
Net receivables	-	0.00000M	0.02M	0.01M	0.17M
Long term debt	0.93M	-	-	-	-
Inventory	2.18M	3.32M	1.75M	1.13M	0.51M
Accounts payable	0.23M	0.18M	0.11M	0.10M	0.05M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-	-	-	-	-
Deferred long term asset charges	-	-	-	-	-
Non current assets total	0.09M	0.11M	0.14M	0.10M	0.05M
Capital lease obligations	0.00000M	0.01000M	0.03M	0.03M	0.00100M
Long term debt total	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	-	0.05M	-0.08400M	-0.03100M	-0.04800M
Change to liabilities	-	-	-	-	-0.47400M
Total cashflows from investing activities	-	-	-	-	-0.04800M
Net borrowings	0.63M	-0.02200M	-0.02200M	-0.01100M	-0.03800M
Total cash from financing activities	1.15M	2.70M	2.92M	0.12M	15.30M
Change to operating activities	-	-	-	-	0.05M
Net income	-1.12400M	-1.83400M	-4.70000M	-3.76400M	-10.04700M
Change in cash	1.68M	1.12M	-1.06200M	-6.10100M	8.71M
Begin period cash flow	5.01M	3.88M	4.95M	11.05M	2.34M
End period cash flow	6.69M	5.01M	3.88M	4.95M	11.05M
Total cash from operating activities	0.49M	-1.57900M	-3.90400M	-6.06700M	-6.62900M
Issuance of capital stock	0.09M	0.89M	1.55M	0.00000M	3.91M
Depreciation	0.04M	0.04M	0.03M	0.04M	0.04M
Other cashflows from investing activities	-	-	-	-	-0.00700M
Dividends paid	-	-	-	-	-
Change to inventory	1.14M	-1.57000M	-0.61600M	-0.62100M	-0.07900M
Change to account receivables	0.00000M	0.02M	-0.00200M	-0.01500M	-0.46500M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	-	-	-	-	3.43M
Change to netincome	-	-	-	-	4.34M
Capital expenditures	0.02M	0.01M	0.05M	0.03M	0.04M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	1.57M	-1.20300M	-0.79300M	-0.53100M	-0.96900M
Stock based compensation	1.46M	2.01M	0.85M	0.97M	2.16M
Other non cash items	-	-	-0.00800M	0.12M	-0.08300M
Free cash flow	0.48M	-1.59400M	-3.95000M	-6.09300M	-6.67000M

Peer Comparison

Sector: Consumer Defensive Industry: Household & Personal Products

Company	Change (CAD)	Price (CAD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
INNO InnoCan Pharma Corporation	-0.25 7.94%	2.90	-	-	1.07	3.71	0.57	116.00
CGII CleanGo Innovations Inc.	- -%	0.65	-	-	42.20	53.07	43.98	1.20
WAY Way of Will Inc.	- -%	0.04	-	-	-	-

Reports Covered

View All

Profile

InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments: Pharmaceuticals and Consumer Wellness. The company's Pharmaceutical segment engages in the development of drug delivery technologies for both human and animal health applications, based on advanced cannabinoids science. It offers a Cannabidiol-loaded Liposome injection Platform (LPT-CBD) that facilitates dosing and release of synthetic cannabidiol into the blood stream for the treatment of chronic pain. The company's Consumer Wellness segment engages in the development and marketing of self-care and hemp-derived cannabidiol beauty products through the brand B.I. Sky. Skincare and Beauty: Its skincare product range includes face creams, serums, masks, soaps, and neck creams for the treatment of dark spot, skin discoloration, hyperpigmentation, and anti-aging . Its pain relief products includes cannabidiol-based topical treatments, such as pain relief sprays and roll-on formulations. InnoCan Pharma Corporation was founded in 2017 and is headquartered in Calgary, Canada.

InnoCan Pharma Corporation

1015, 926 ? 5 Avenue SW, Calgary, AB, Canada, T2P 0N7

516 210 4025
https://innocanpharma.com

Key Executives

Name	Title	Year Born
Ms. Iris Bincovich	CEO & Interim Chairwoman	1970
Mr. Nelson Harvey Halpern F.C.A., FCPA	Chief Financial Officer	1959
Mr. Roni Kamhi	COO, CEO of B.I. Sky Global LTD & Director	1976
Mr. Eyal Flom L.L.M., M.B.A.	Company Secretary, General Counsel & Director	1967
Dr. Eyal Kalo	Vice President of Research & Development	1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.